Cambridge Healthtech Institute’s 6th Annual

Immunomodulatory Therapeutic Antibodies for Cancer

Emerging Targets, Combinations, and Antibody Engineering for Next-Generation Immunotherapy

August 27-28, 2018

Despite the success of immunomodulatory antibodies in immuno-oncology, challenges remain in expanding the target space, engineering next-generation antibodies with improved efficacy and safety, and addressing innate and acquired resistance to immunotherapy. CHI’s Sixth Annual Immunomodulatory Therapeutic Antibodies for Cancer meeting will explore next-generation immunotherapies, emerging targets and combinations, and strategies for overcoming resistance. It will provide case studies of antibody development in immuno-oncology from preclinical to clinical development.


Preliminary Agenda

EMERGING IMMUNE CHECKPOINT TARGETS

Understanding Immune Checkpoint TIM-3 Biology and Implications for Targeting TIM-3 for Cancer Immunotherapy

Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research

New Immune Checkpoints for Human Cancer Immunotherapy

Xingxing Zang, PhD, Professor and Louis Goldstein Swan Endowed Chair, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine

Comprehensive Analysis of the Clinical Immuno-Oncology Landscape

Aiman Shalabi, PharmD, CMO, Cancer Research Institute

ATOR-1017 - A Tumor-Directed Fcγ-Receptor Cross Linking Dependent 4-1BB Agonistic Antibody

Christina Furebring, PhD, Senior Vice President, R&D, Alligator Bioscience

EOS884448, an hIgG1 mAb Anti-TIGIT, Induces T Cell Mediated Anti-Tumor Immune Response and Demonstrates Strong Anti-Tumor Immunity in Monotherapy

Xavier Leroy, PhD, Director, Drug Discovery, iTeos Therapeutics


THERAPEUTIC STRATEGIES TO OVERCOME RESISTANCE
TO CHECKPOINT INHIBITORS

Overcoming Resistance to PD-1 Inhibition in Pancreatic Cancer

Osama Rahma, MD, Assistant Professor of Medicine, Harvard Medical School; Center for Immuno-oncology, Dana-Farber Cancer Institute


BISPECIFIC ANTIBODIES FOR COMBINATION THERAPY

Overview of Bispecific Antibodies

Rakesh Dixit, DABT Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune

Coordinate Engagement of T-Cell Regulatory Pathways Using Bispecific DART® Molecules

Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics

T Cell-Dependent Bispecific Antibodies

Teemu Junttila, PhD, Senior Scientist, Genentech



For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com


For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

#IOSummit